Abramson Cancer Center at University of Pennsylvania (Data Collection Only)
Welcome,         Profile    Billing    Logout  
 9 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moskowitz, Alison
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, Canada, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
NCT03179917: Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Active, not recruiting
2
22
US
Pembrolizumab, Involved Site Radiation Therapy
Memorial Sloan Kettering Cancer Center
Hodgkin Lymphoma
06/26
06/26
NCT03618550: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
257
US
pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
08/25
08/25
NCT02974647: Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Recruiting
2
82
US
Ruxolitinib
Memorial Sloan Kettering Cancer Center, Cornell University, Dana-Farber Cancer Institute, Thomas Jefferson University
Lymphoma
11/25
11/25
NCT03728972: Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Active, not recruiting
2
19
US
Pembrolizumab
Memorial Sloan Kettering Cancer Center
NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
11/25
11/25
NCI-2022-02385, NCT05592015: Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Recruiting
2
28
US
Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424
Jonathan Brammer
T-Cell Large Granular Lymphocyte Leukemia
12/25
12/25
NCT03179930: Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Active, not recruiting
2
47
US
Entinostat, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Syndax Pharmaceuticals
Lymphoma, Relapsed, Refractory
06/25
06/25
A051902, NCT04803201: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Recruiting
2
170
US
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
06/26
06/26
NCT03587844: Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Recruiting
2
58
US
brentuximab vedotin
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
07/26
07/26
NCT04960618: Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

Recruiting
2
28
US
Gemcitabine, Pembrolizumab
Memorial Sloan Kettering Cancer Center
Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome, Sézary, Advanced Mycosis Fungoides
07/25
07/25
CA209-447, NCT03033914: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Active, not recruiting
1/2
82
Canada, US
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb, Barbara Ann Karmanos Cancer Institute, British Columbia Cancer Agency
Hodgkin Lymphoma
01/26
01/26
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
133
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23
NCT05010005: A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Recruiting
1
70
US
Ruxolitinib, Duvelisib
Memorial Sloan Kettering Cancer Center
T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
08/26
08/26
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
NCT02106611: Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors

Active, not recruiting
N/A
133
US
Clinical Assessment, Stress cardiac MRI, Stress echocardiogram
Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University
Hodgkin Lymphoma Survivor
04/25
04/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moskowitz, Alison
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, Canada, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
NCT03179917: Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Active, not recruiting
2
22
US
Pembrolizumab, Involved Site Radiation Therapy
Memorial Sloan Kettering Cancer Center
Hodgkin Lymphoma
06/26
06/26
NCT03618550: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
257
US
pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
08/25
08/25
NCT02974647: Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Recruiting
2
82
US
Ruxolitinib
Memorial Sloan Kettering Cancer Center, Cornell University, Dana-Farber Cancer Institute, Thomas Jefferson University
Lymphoma
11/25
11/25
NCT03728972: Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Active, not recruiting
2
19
US
Pembrolizumab
Memorial Sloan Kettering Cancer Center
NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
11/25
11/25
NCI-2022-02385, NCT05592015: Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Recruiting
2
28
US
Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424
Jonathan Brammer
T-Cell Large Granular Lymphocyte Leukemia
12/25
12/25
NCT03179930: Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Active, not recruiting
2
47
US
Entinostat, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Syndax Pharmaceuticals
Lymphoma, Relapsed, Refractory
06/25
06/25
A051902, NCT04803201: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Recruiting
2
170
US
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
06/26
06/26
NCT03587844: Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Recruiting
2
58
US
brentuximab vedotin
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
07/26
07/26
NCT04960618: Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

Recruiting
2
28
US
Gemcitabine, Pembrolizumab
Memorial Sloan Kettering Cancer Center
Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome, Sézary, Advanced Mycosis Fungoides
07/25
07/25
CA209-447, NCT03033914: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Active, not recruiting
1/2
82
Canada, US
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb, Barbara Ann Karmanos Cancer Institute, British Columbia Cancer Agency
Hodgkin Lymphoma
01/26
01/26
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
133
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23
NCT05010005: A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Recruiting
1
70
US
Ruxolitinib, Duvelisib
Memorial Sloan Kettering Cancer Center
T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
08/26
08/26
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
NCT02106611: Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors

Active, not recruiting
N/A
133
US
Clinical Assessment, Stress cardiac MRI, Stress echocardiogram
Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University
Hodgkin Lymphoma Survivor
04/25
04/25

Download Options